Use of Botulinum Toxin Type a in Management of Adult Spasticity - A European Consensus Statement

Anthony B. Ward, Miguel Aguilar, Zegers De Beyl, Susanne Gedin, Petr Kanovsky, Franco Molteni, Jorg Wissel and Anton Yakovleff From the Department of Rehabilitation Medicine, North Staffordshire Hospital, Stoke-on Trent, UK, Department of Neurology, Hospital Mutua Terrassa, Barcelona, Spain, Department of Neurology, Hopital Erasme, Universite Libre de Bruxelles, Belgium, Department of Neurology, Helsingborg Hospital, Sweden, Department of Neurology, Masaryk University, Brno, Czech Republic, Movement Disorders Rehabilitation Unit, Valduce Rehabilitation Centre, Costa Masnaga, Lecco, Italy, Department of Neurology, Clinic for Neurorehabilitation, Beelitz-Heilstatten, Germany, Clinical Neurology, Universite de Paris V-Rene Descartes, France